Pumitamig is an investigational PD-L1×VEGF-A bispecific immunomodulator jointly developed by BioNTech and Bristol Myers Squibb, designed to simultaneously target immune evasion and tumor angiogenesis. 

Emerging as a key competitor in the rapidly evolving PD-(L)1/VEGF space, pumitamig has demonstrated encouraging efficacy in the Phase II ROSETTA Lung-02 trial, achieving a 70% objective response rate and a 100% disease control rate, with results broadly comparable to those reported for ivonescimab. Notably, it is the first investigational PD-(L) 1×VEGF bispecific to present global data showing promising activity in combination with chemotherapy across NSCLC subtypes and PD-L1 expression levels. While ivonescimab currently appears to hold a potential first-to-market advantage, pumitamig is advancing through a comprehensive global Phase III development program, including the pivotal ROSETTA Lung-02 study and two additional registrational trials, positioning it as a leading challenger in the emerging PD-(L)1/VEGF bispecific landscape. The study results are summarized below:

Efficacy Highlights (ROSETTA Lung-02 Phase II Interim Analysis)

• Confirmed ORR was 57.1% in patients with non-squamous NSCLC.

• Confirmed ORR was 68.4% in patients with squamous NSCLC.

• Disease Control Rate (DCR) reached 100% across evaluable patients.

• At the selected 1500 mg dose, ORR increased to: 63.6% in non-squamous NSCLC; 72.7% in squamous NSCLC.

• Responses were observed regardless of PD-L1 status: 47.6% ORR in PD-L1 TPS <1%; 77.8% ORR in PD-L1 TPS 1–49%; 100% ORR in PD-L1 TPS ≥50%.

• The broad efficacy profile supported advancement into the global Phase III portion of the trial.

Safety Highlights

• Grade ≥3 treatment-related adverse events (TRAEs) occurred in 48.8% of patients.

• Grade ≥3 TRAEs related to pumitamig were reported in 23.3% of patients: Treatment discontinuation due to TRAEs occurred in 9.3% of patients (4 patients).

• Immune-related adverse events (irAEs) were reported in 37.2% of patients: Grade ≥3 irAEs occurred in 4.7% of patients.

• Bleeding events were reported in 20.9% of patients: Only one Grade 3 bleeding event was observed.

• No unexpected safety signals were identified, and the overall safety profile was considered manageable.

KOL insights

“Despite significant immuno-oncology advances in the treatment of NSCLC, most advanced diseases relapse on or after a PD-(L) 1 checkpoint inhibitor treatment,1 indicating that targeting this immunologic pathway alone is insufficient to achieve durable responses.” –Expert Opinion

“With one of the broadest registrational programs in the class, we are focused on accelerating the development of pumitamig together with BioNTech, with the goal of delivering meaningful benefit to patients, including those who have been left behind by current therapies.”–Expert Opinion

Conclusion 

With more than 500,000 lung cancer cases across the 7MM and a PD-L1 NSCLC market valued at approximately USD 11 billion in 2025, the need for more effective frontline therapies remains substantial. While pembrolizumab-based regimens continue to dominate the first-line treatment landscape for patients without actionable driver mutations, the emergence of PD-(L)1×VEGF bispecific antibodies is poised to reshape the competitive environment. Pumitamig, a novel PD-L1×VEGF-A bispecific immunomodulator developed by BioNTech and Bristol Myers Squibb, has become the first agent in this class to generate encouraging global efficacy data in combination with chemotherapy across NSCLC subtypes and PD-L1 expression levels. These findings support its potential to evolve into a next-generation immunotherapy backbone and challenge established standards of care.

The competitive landscape is rapidly intensifying, with Akeso and Summit Therapeutics' ivonescimab currently leading the PD-(L)1×VEGF space following positive Phase III results, while pumitamig advances through a broad global Phase III development program. If ongoing studies confirm its early promise, pumitamig could emerge as a major competitor to both ivonescimab and existing PD-(L)1 inhibitors, including pembrolizumab and atezolizumab, potentially establishing a new treatment paradigm in frontline NSCLC.